Vascular Diseases Clinical Trial
Official title:
A Randomized Trial of Electronic Integration of Care for Better Vascular Outcomes: The Compete III Study Computerization of Medical Practices for the Enhancement of Therapeutic Effectiveness (COMPETE III)
Vascular diseases (cardiac events, strokes, peripheral vascular disease) remain the number
one killer in Canadian society as well as the leading cause of hospitalization and days
spent in the hospital. A 1996 estimate placed Ontario's vascular disease financial burden at
$5.5 billion in total. Any intervention which lowers vascular risk, will have a direct
impact on the quantity and quality of life and costs of health care. Further integration of
health professionals in teams focused on chronic disease management in individuals and
populations is also ripe for further evaluation. Increased collaboration between family
physicians, physician specialists, nurse practitioners, and pharmacists are generally
thought to be beneficial for patient outcomes, but the literature is inconclusive and their
cost-effectiveness is unproven. In addition, combining centralized electronic up-to-date
information on the patient's status with evidence-based recommendations and the ability to
communicate either electronically or by phone is expected to result in improved access to
care, quality of care, continuity of care and increase cost-effectiveness of chronic disease
management.
COMPETE III builds on the researchers' previous work to study an electronic vascular
tracking and decision support system shared by patients and their physicians, combined with
a clinical care coordinator and automated telephone support system. The researchers are
evaluating its impact on vascular risk processes and outcomes, perceived usefulness, ease of
use, need for improvement, medication adherence, quality of life and patient goals and
motivation.
Study hypothesis: Patients at increased risk of vascular events, if connected with their
family physicians, medical specialists and care coordinator via an electronic network (Web,
fax and telephone) sharing an intensive tracking, advice and support program, will lower
their vascular risk more than those in usual care.
COMPETE is Canada's original electronic medical record research network and specializes in
the rigorous development, implementation and evaluation of electronic technologies in health
care. COMPETE III will build on COMPETE II to incorporate the latest evidence on:
1. the management of diabetes, hypertension, dyslipidemia and previous vascular events,
2. improving patient-clinician interactions,
3. the use of technology to enhance the quality, safety and efficiency of care and
4. motivational strategies to change both patient and clinician behaviour.
Specifically, the researchers will:
1. Expand the disease focus to a vascular risk population (diabetes, hypertension,
dyslipidemia or previous vascular event);
2. Expand the electronic care network beyond patients and primary care providers to also
include specialists (physician specialists, specialty nurse clinicians, etc);
3. Expand the geographical network from Hamilton area, and Ottawa to include other primary
care reform (PCR), Ontario Family Health Networks (OFHN) or EHR using sites;
4. Tighten the integration with the leading Ontario EHR products and concentrate on those
meeting the new Ontario Smart Systems for Health Clinical Management System
specifications,
5. Strengthen the clinical decision support by offering evidence-based algorithms specific
to the patient, provide specific formulary advice - drug listing, Limited Use
prescriptions and codes, Section 8 criteria and form letters;
6. Improve the researchers pharmacosurveillance network which pursues reasons for starting
and stopping medications by seeking adherence information directly from patients;
7. Provide direct links via Internet for patients and clinicians to best evidence about
vascular disease,
8. Improve the automated telephone support (ATS);
9. Support physicians in managing this advanced care network by providing clinical care
coordinators, either nurse clinicians or clinical pharmacists;
10. Use HL-7 messaging standards as per Canada Health Infoway guidelines;
11. Rigorously evaluate the cost-effectiveness of our package intervention in order to
provide specific advice to health planners and payers on costs and benefits.
;
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05971407 -
The Effect of Chronic Remote Ischaemic Preconditioning on Blood Pressure in Older Adults
|
N/A | |
| Enrolling by invitation |
NCT03683186 -
A Study Evaluating the Long-Term Efficacy and Safety of Ralinepag in Subjects With PAH Via an Open-Label Extension
|
Phase 3 | |
| Recruiting |
NCT04390672 -
Multivessel TALENT
|
N/A | |
| Recruiting |
NCT04584632 -
The Efemoral Vascular Scaffold System (EVSS) for the Treatment of Patients With Symptomatic Peripheral Vascular Disease From Stenosis or Occlusion of the Femoropopliteal Artery
|
N/A | |
| Completed |
NCT01915368 -
Determining Optimal Post-Stroke Exercise (DOSE)
|
N/A | |
| Completed |
NCT01684826 -
X-ray Dose Reduction Study for Cardiac Angiography and Intervention
|
N/A | |
| Completed |
NCT01417910 -
Predictors of Post Operative Outcome in Peripheral Vascular Surgical Patients
|
N/A | |
| Terminated |
NCT00935766 -
Effect of Fish Oil (Omega-3 Fatty Acids) on Arteries
|
Phase 3 | |
| Unknown status |
NCT01748383 -
The Long-term and Short-term Efficacy and Safety of Transplantation Autologous Bone Marrow Cells (BMCs) in Patients With the First STEMI (ST Segment Elevation Myocardial Infarction)
|
Phase 2 | |
| Recruiting |
NCT05907564 -
Aventus Thrombectomy System Pulmonary Embolism Clinical Study
|
N/A | |
| Recruiting |
NCT03732612 -
Inflammation in Vascular Disease
|
||
| Completed |
NCT00000614 -
Prevention of Recurrent Venous Thromboembolism (PREVENT)
|
Phase 3 | |
| Completed |
NCT00000479 -
Women's Health Study (WHS): A Randomized Trial of Low-dose Aspirin and Vitamin E in the Primary Prevention of Cardiovascular Disease and Cancer
|
Phase 3 | |
| Completed |
NCT00000539 -
Arterial Disease Multifactorial Intervention Trial (ADMIT)
|
Phase 3 | |
| Completed |
NCT00000530 -
Raynaud's Treatment Study (RTS)
|
Phase 3 | |
| Completed |
NCT00000474 -
Prevention and Treatment of Hypertension Study (PATHS)
|
Phase 3 | |
| Completed |
NCT00000528 -
Trials of Hypertension Prevention (TOHP)
|
Phase 3 | |
| Completed |
NCT00000509 -
Potassium and Sodium to Control Blood Pressure in Hypertensives
|
Phase 3 | |
| Completed |
NCT00000501 -
Hypertension Prevention Trial (HPT) Feasibility Study
|
Phase 2 | |
| Completed |
NCT00000499 -
Systolic Hypertension in the Elderly Program (SHEP) (Pilot Study)
|
Phase 2 |